[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=e3c108591279f54615ef26978a58b56b5a524f8ac746509e9c2766d40bdbbe40",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930100,
      "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "id": 136332715,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=e3c108591279f54615ef26978a58b56b5a524f8ac746509e9c2766d40bdbbe40"
    }
  },
  {
    "ts": null,
    "headline": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=abdbf434f69351da4e2eca1c64275ccfe67df049aed3b95f4a7cb38cb72dcb36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917801,
      "headline": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
      "id": 136310639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=abdbf434f69351da4e2eca1c64275ccfe67df049aed3b95f4a7cb38cb72dcb36"
    }
  },
  {
    "ts": null,
    "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
    "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
    "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917800,
      "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
      "id": 136295231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
      "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution",
    "summary": "The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...",
    "url": "https://finnhub.io/api/news?id=22a674f007240d8db43111f825528b8e55e9dff87a61b4f11b0871ef520c91cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917211,
      "headline": "Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution",
      "id": 136294360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...",
      "url": "https://finnhub.io/api/news?id=22a674f007240d8db43111f825528b8e55e9dff87a61b4f11b0871ef520c91cf"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Amgen Inc. (AMGN) a Buy Now?",
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=d8b73144d425e2ba3abdf42ff97c49df9f24beec08811e752714d05a6313ae4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917202,
      "headline": "Is Trending Stock Amgen Inc. (AMGN) a Buy Now?",
      "id": 136294361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=d8b73144d425e2ba3abdf42ff97c49df9f24beec08811e752714d05a6313ae4e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136294362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136292433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d"
    }
  }
]